Estimation of Willingness-to-Pay for breast cancer treatments through Contingent Valuation Method in Japanese breast cancer patients(JCOG1709A)
Not Applicable
Recruiting
- Conditions
- 1)Unilateral breast cancer patients who fulfill either i) or ii) below i)Primary breast cancer of clinical stage 0 through III for which surgery and /or chemotherapy and / or radiotherapy has been completed as initial treatment and that is currently undergoing regular follow-up observations or postoperative endocrine therapy ii)Undergoing endocrine therapy or first-line through third-line chemotherapy for metastatic or recurrent cancer for at least 2 months
- Registration Number
- JPRN-UMIN000037445
- Lead Sponsor
- Japan Clinical Oncology Group (JCOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 1764
Inclusion Criteria
Not provided
Exclusion Criteria
Nothing
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie patient willingness-to-pay for breast cancer therapies in JCOG1709A?
How does the contingent valuation method assess treatment preferences in Japanese breast cancer patients?
What biomarkers correlate with adherence to endocrine therapy in unilateral breast cancer patients?
Are there comparative effectiveness studies of endocrine vs. chemotherapy in metastatic breast cancer patient outcomes?
What adverse events are associated with first-line to third-line chemotherapy in Japanese breast cancer populations?